RxDoctor Payments Data

David Isaacs, MD

Neurology · Nashville, TNNPI 1245520436

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Teva Pharmaceuticals USA, Inc. accounts for 66.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in TN, where the typical reported total is $2,246.

$102in general payments, 2019–2025

Across 6 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$68
  • Takeda Pharmaceuticals U.S.A., Inc.$35
$128,347in research payments, 2019–2025

Across 3 payments — averaging $42,782 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$107K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$21K

What the payments were for

  • Food & beverage$102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$102 in reported general payments places this provider in the 20th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,582
Medicare patients
21
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine44$494,935
Austedo XrDeutetrabenazine28$391,117
Guanfacine Hcl17$1,084
Guanfacine Hcl ErGuanfacine Hcl24$825
Fluphenazine Hcl13$594
Carbidopa-LevodopaCarbidopa/Levodopa12$420
Aripiprazole19$315
Gabapentin24$284
Topiramate15$247
Clonazepam26$233
Sertraline Hcl19$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$68$886,05272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →